RecruitingPhase 1NCT05562791

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Pilot Study of 68Gallium PSMA-PET/CT in Patients With Metastatic Urothelial Carcinoma or Melanoma


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

20 participants

Start Date

Sep 28, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a special imaging scan using a radioactive tracer called 68Gallium PSMA (Ga-PSMA PET/CT) in people with bladder cancer or skin cancer (melanoma). Although this scan is already used in prostate cancer, researchers want to see if it can also help locate and track tumors in these other cancer types. **You may be eligible if...** - You have confirmed metastatic bladder cancer (urothelial carcinoma) with spread outside the pelvis, OR confirmed metastatic melanoma - You are 18 or older - Your functional status allows you to undergo a PET scan (able to lie still) - You have assessable/measurable lesions on imaging **You may NOT be eligible if...** - Your bladder cancer has only spread to pelvic lymph nodes or only to bones - You cannot lie flat or stay still for a PET scan - You are receiving active treatment for another cancer - You are pregnant - You are on a therapeutic trial where this scan would interfere Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[68Ga]PSMA

68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.

DIAGNOSTIC_TESTPET/CT imaging

68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.


Locations(7)

Memorial Sloan Kettering Basking Ridge (Consent Only)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)

Commack, New York, United States

Memorial Sloan Kettering West Harrison (All Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05562791


Related Trials